Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.8
(-0.23%)
CNY 42.8
(-0.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 651.24 Million CNY | -50.94% |
| 2022 | 1.32 Billion CNY | 96.88% |
| 2021 | 674.16 Million CNY | 3.57% |
| 2020 | 650.92 Million CNY | 247.63% |
| 2019 | 187.24 Million CNY | -41.05% |
| 2018 | 317.61 Million CNY | 242.84% |
| 2017 | -222.36 Million CNY | 31.32% |
| 2016 | -323.77 Million CNY | 42.36% |
| 2015 | -561.73 Million CNY | -22.64% |
| 2014 | -458.04 Million CNY | 44.47% |
| 2013 | -824.83 Million CNY | 33.45% |
| 2012 | -1.23 Billion CNY | -149.24% |
| 2011 | -497.29 Million CNY | -40.53% |
| 2010 | -353.86 Million CNY | -245.69% |
| 2009 | -102.36 Million CNY | -103.83% |
| 2008 | -50.22 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 594.38 Million CNY | -25.1% |
| 2024 Q1 | 587.83 Million CNY | -9.74% |
| 2024 Q2 | 802.58 Million CNY | 36.53% |
| 2023 Q1 | 706.13 Million CNY | -46.8% |
| 2023 FY | 651.24 Million CNY | -50.94% |
| 2023 Q4 | 651.24 Million CNY | -7.32% |
| 2023 Q3 | 702.66 Million CNY | 8.31% |
| 2023 Q2 | 648.75 Million CNY | -8.13% |
| 2022 FY | 1.32 Billion CNY | 96.88% |
| 2022 Q4 | 1.32 Billion CNY | -9.41% |
| 2022 Q3 | 1.46 Billion CNY | 50.43% |
| 2022 Q2 | 973.98 Million CNY | -0.32% |
| 2022 Q1 | 977.12 Million CNY | 44.94% |
| 2021 Q3 | 796.21 Million CNY | 52.5% |
| 2021 Q2 | 522.1 Million CNY | 322.64% |
| 2021 FY | 674.16 Million CNY | 3.57% |
| 2021 Q1 | 123.53 Million CNY | -81.02% |
| 2021 Q4 | 674.16 Million CNY | -15.33% |
| 2020 Q1 | 691.5 Million CNY | 269.3% |
| 2020 Q2 | 857.2 Million CNY | 23.96% |
| 2020 Q3 | 953.01 Million CNY | 11.18% |
| 2020 Q4 | 650.92 Million CNY | -31.7% |
| 2020 FY | 650.92 Million CNY | 247.63% |
| 2019 Q1 | 654.7 Million CNY | 106.13% |
| 2019 Q3 | 528.29 Million CNY | 2.97% |
| 2019 Q4 | 187.24 Million CNY | -64.56% |
| 2019 FY | 187.24 Million CNY | -41.05% |
| 2019 Q2 | 513.06 Million CNY | -21.63% |
| 2018 FY | 317.61 Million CNY | 242.84% |
| 2018 Q1 | 261.82 Million CNY | 217.74% |
| 2018 Q2 | 36.84 Million CNY | -85.93% |
| 2018 Q3 | 8.82 Million CNY | -76.05% |
| 2018 Q4 | 317.61 Million CNY | 3498.32% |
| 2017 Q4 | -222.36 Million CNY | -360.51% |
| 2017 FY | -222.36 Million CNY | 31.32% |
| 2017 Q3 | 85.35 Million CNY | 117.12% |
| 2017 Q2 | -498.45 Million CNY | 2.16% |
| 2017 Q1 | -509.46 Million CNY | -57.35% |
| 2016 Q2 | -326.62 Million CNY | 9.94% |
| 2016 FY | -323.77 Million CNY | 42.36% |
| 2016 Q1 | -362.68 Million CNY | 35.43% |
| 2016 Q4 | -323.77 Million CNY | -155.35% |
| 2016 Q3 | -126.79 Million CNY | 61.18% |
| 2015 Q2 | -420.07 Million CNY | 37.48% |
| 2015 FY | -561.73 Million CNY | -22.64% |
| 2015 Q4 | -561.73 Million CNY | -1.6% |
| 2015 Q3 | -552.91 Million CNY | -31.62% |
| 2015 Q1 | -671.88 Million CNY | -46.69% |
| 2014 FY | -458.04 Million CNY | 44.47% |
| 2014 Q3 | -454.89 Million CNY | 36.82% |
| 2014 Q2 | -720.04 Million CNY | 28.14% |
| 2014 Q1 | -1 Billion CNY | -21.48% |
| 2014 Q4 | -458.04 Million CNY | -0.69% |
| 2013 Q3 | -812.46 Million CNY | 30.14% |
| 2013 FY | -824.83 Million CNY | 33.45% |
| 2013 Q4 | -824.83 Million CNY | -1.52% |
| 2013 Q1 | -1.07 Billion CNY | 13.54% |
| 2013 Q2 | -1.16 Billion CNY | -8.52% |
| 2012 Q2 | -1.02 Billion CNY | 3.96% |
| 2012 Q3 | -1.18 Billion CNY | -14.93% |
| 2012 Q4 | -1.23 Billion CNY | -4.83% |
| 2012 FY | -1.23 Billion CNY | -149.24% |
| 2012 Q1 | -1.07 Billion CNY | -115.42% |
| 2011 FY | -497.29 Million CNY | -40.53% |
| 2011 Q2 | -389.58 Million CNY | 0.0% |
| 2011 Q3 | -420.56 Million CNY | -7.95% |
| 2011 Q4 | -497.29 Million CNY | -18.24% |
| 2010 FY | -353.86 Million CNY | -245.69% |
| 2010 Q4 | -353.86 Million CNY | 0.0% |
| 2009 FY | -102.36 Million CNY | -103.83% |
| 2008 FY | -50.22 Million CNY | 0.0% |